Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform. https://t.co/4c4oQwY9G6 https://t.co/iRa7wG5yOv

Watch: Zoster Management and Vaccination Drs. Janet Pope and Kevin Winthrop at EULAR 2023 in Milan, Italy. https://t.co/JcZNaeYuqh https://t.co/WF1PdlIbTO

Pegloticase Plus Methotrexate in Refractory Gout - MIRROR Study 12 mos. Results The 12-month safety and efficacy of pegloticase + methotrexate (MTX) in the MIRROR trial shows continued efficacy and tophi resolution after 12 months of therapy. https://t.co/8Jhy7gebMD https://t.co/ihZddj7b36

Biologics Keep Early RA in Check for at Least One Year Treatment with at least some biologic drugs significantly reduced 1-year progression of early rheumatoid arthritis (RA) relative to classical small-molecule agents, researchers reported. https://t.co/FBFX53lZfp https://t.co/l1RapKWlFk

Metanalysis of 8 RCT, 188751 pts assessed mortality risk & FM. Overall, all-cause mortality increased in FM (HR 1.27, 1.04 to 1.51), but not in subgroup Dx by 1990 criteria. Increased SMR for accidents, infxn, suicide & decreased for cancer (0.82) https://t.co/Ujv8KP8FJK https://t.co/lNGUM0wB3O

ICYMI: RA Disease Activity and Alcohol Use https://t.co/tXuAJ4GRl4 https://t.co/3ieVw8BcIs

35 SLE pts Rx w/ RTX x 3 ys-anti-RTX antibodies found @3 yrs in 64%, higher if previously RTX treated (vs naive). ADA+ had signif lower median RTX levels at 6 mos (P = 0.0018) and increased relapse rates. In vitro showed neutralizing capacity these Abs https://t.co/oV7nHxiS4s https://t.co/p55MvcLDFn

Metanalysis 62 RCTs & 16 LTE RCTs looks at neoplasia risk in JAKi, TNFi, MTX, PBO. Total CA rate=1.15/100PYs in RCTs. No diff in all CA between JAKi vs PBO or JAKi vs MTX (IRR 0.77); but JAKi had more CA than TNFi (1.50; 1.16, 1.94) https://t.co/aiJHQ5oPqt https://t.co/8MjJv728sh

RA Biologics Lower COVID-19 Deaths, but Not Recovery Time Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care? https://t.co/o56m9WumiC. https://t.co/GHe1RprDnk

Baricitinib Effective in JIA Subsets A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo. https://t.co/0CMzVCgsG8 https://t.co/NGE1pxsmcb

Commercial claims analysis of 21,044 pts w/ simultaneous B/L TKA vs 126,264 matched unilateral TKA. 90 day risk showed B/L TKA had signif more pulmonary embolism (aOR 2.13), CVA (2.21), acute anemia (2.06), transfusion (7.8), 90d readmission (1.35) https://t.co/ZW7fa3fbfC https://t.co/nVqRospVIV

JAMA: Prophylaxis for Pneumocystis Pneumonia - indications and Rx - Immuncompromised and Immunodeficient - Pts on Hi Dose Steroids - ANCA–associated vasculitis https://t.co/2VhLxc4VNo https://t.co/cXuY4Manrk